Safety and Efficacy of an Intravaginal Prebiotic Gel in the Prevention of Recurrent Bacterial Vaginosis: A Randomized Double-Blind Study

Table 2

Nugent score at the different visits.

		Treatment
		Active		Placebo
		𝑁=18	%	𝑁=21	%
Nugent scores at D0	0–3: Negative	13	72.22	14	66.66
	4–6: Intermediate	4	22.22	6	28.57
	>7: Indicative of BV	1	5.56	1	4.77
	Median, (min–max)	0 (0–7)		1 (0–7)
	P value; (active versus placebo)	0.296
Nugent scores at D8	0–3: Negative	18	100.00	14	66.66
	4–6: Intermediate	0	0.00	6	28.57
	>7: Indicative of BV	0	0.00	1	4.77
	Median, (min–max)	0 (0–3)		1 (0–9)
	P value; (active versus placebo)	0.0478
Nugent scores at D16	0–3: Negative	18	100.00	16	76.19
	4–6: Intermediate	0	0.00	4	19.00
	>7: Indicative of BV	0	0.00	1	4.81
	Median, (min-max)	0 (0–2)		0 (0–7)
	P value; (active versus placebo)	0.0157